NYSE:ANVS

Annovis Bio Competitors

$26.54
+0.03 (+0.11 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.25
Now: $26.54
$26.87
50-Day Range
$24.86
MA: $29.36
$38.44
52-Week Range
$2.93
Now: $26.54
$47.99
Volume133,126 shs
Average Volume301,579 shs
Market Capitalization$184.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Annovis Bio (NYSE:ANVS) Vs. GMTX, SGTX, IVA, TERN, ANGN, and SNSE

Should you be buying ANVS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Annovis Bio, including Gemini Therapeutics (GMTX), Sigilon Therapeutics (SGTX), Inventiva (IVA), Terns Pharmaceuticals (TERN), Angion Biomedica (ANGN), and Sensei Biotherapeutics (SNSE).

Annovis Bio (NYSE:ANVS) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Gemini Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Gemini TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Gemini Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Gemini Therapeutics00403.00

Gemini Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 66.41%. Given Gemini Therapeutics' higher probable upside, analysts plainly believe Gemini Therapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Gemini Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Gemini TherapeuticsN/AN/AN/AN/AN/A

Summary

Gemini Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Sigilon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Sigilon Therapeutics01302.75

Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 202.65%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Summary

Sigilon Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
InventivaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Inventiva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Inventiva10402.60

Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 89.31%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Inventiva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
InventivaN/AN/AN/AN/AN/A

Summary

Inventiva beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Terns Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Terns Pharmaceuticals00303.00

Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 61.12%. Given Terns Pharmaceuticals' higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Terns Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Terns Pharmaceuticals beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Angion Biomedica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Angion BiomedicaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Angion Biomedica, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Angion Biomedica00403.00

Angion Biomedica has a consensus target price of $59.3333, suggesting a potential upside of 283.29%. Given Angion Biomedica's higher probable upside, analysts plainly believe Angion Biomedica is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Angion Biomedica's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Angion BiomedicaN/AN/AN/AN/AN/A

Summary

Angion Biomedica beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Sensei Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Sensei Biotherapeutics00403.00

Sensei Biotherapeutics has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Sensei Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Sensei Biotherapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.


Annovis Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22+6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76+1.7%$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44+2.2%$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93+2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48+1.4%$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13+4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85+2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93+2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23+2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83+1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07+6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00+0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54+0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28+5.1%$234.78 millionN/A0.00News Coverage
GANX
Gain Therapeutics
0.0$13.98+0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06+0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81+0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09+9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64+3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66+6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62+0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17+2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87+1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66+1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86+23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90+19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02+4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21+15.9%$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78+5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94+0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89+8.0%$0.00N/A0.00High Trading Volume
Gap Down
SCPS
Scopus BioPharma
1.4$7.57+6.2%$0.00N/A0.00Gap Down
VECT
VectivBio
0.0$24.23+29.8%$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.